Pei Zhou1, Xueying Wu2, Huan Chen2, Ying Hu3, Henghui Zhang4, Lijia Wu2, Ying Yang2, Beibei Mao2, Huaqing Wang1. 1. Department of Medical Oncology, Tianjin Union Medical Center, The Affiliated Hospital of Nankai University, Tianjin, China. 2. Genecast Precision Medicine Technology Institute, Beijing, China. 3. Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. 4. Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Abstract
BACKGROUND: Microsatellite-stable (MSS) colon adenocarcinoma (COAD) patients are not sensitive to immune checkpoint inhibitors. Here, we focused on analyzing the relationship between homologous recombination repair (HRR)-related gene mutations and clinical immunotherapy responses in MSS COAD. METHODS: The mutational landscape was profiled in a cohort of 406 Chinese COAD patients via next-generation sequencing (NGS). Correlations between HRR gene mutations and tumor immunity or clinical outcomes in two COAD genomic datasets were analyzed via bioinformatics. RESULTS: In the Chinese cohort, seventy (17%) patients exhibited genomic alterations in HRR genes; ATM (9%), BRCA2 (4%), ATR (3%), RAD50 (3%) and BRIP1 (3%) were the most frequently mutated. In the MSK-IMPACT COAD cohort (immune checkpoint inhibitor-treated), HRR-mut patients (n=34) survived longer than HRR-wt patients (n=50) (log-rank P < 0.01). Based on the TCGA MSS COAD cohort, HRR gene mutations increased immune activities, such as infiltration of cytotoxic cells (P < 0.05) and exhausted CD8+ T cells (P < 0.01), and increased the IFN-γ scores (P < 0.05). The results differed in MSI-H COAD patients (all P > 0.05). CONCLUSION: HRR gene mutations significantly increased immune activities in MSS COAD patients, implying the feasibility of the HRR-mut status as an immunotherapy response predictor in MSS COAD.
BACKGROUND: Microsatellite-stable (MSS) colon adenocarcinoma (COAD) patients are not sensitive to immune checkpoint inhibitors. Here, we focused on analyzing the relationship between homologous recombination repair (HRR)-related gene mutations and clinical immunotherapy responses in MSS COAD. METHODS: The mutational landscape was profiled in a cohort of 406 Chinese COAD patients via next-generation sequencing (NGS). Correlations between HRR gene mutations and tumor immunity or clinical outcomes in two COAD genomic datasets were analyzed via bioinformatics. RESULTS: In the Chinese cohort, seventy (17%) patients exhibited genomic alterations in HRR genes; ATM (9%), BRCA2 (4%), ATR (3%), RAD50 (3%) and BRIP1 (3%) were the most frequently mutated. In the MSK-IMPACT COAD cohort (immune checkpoint inhibitor-treated), HRR-mut patients (n=34) survived longer than HRR-wt patients (n=50) (log-rank P < 0.01). Based on the TCGA MSS COAD cohort, HRR gene mutations increased immune activities, such as infiltration of cytotoxic cells (P < 0.05) and exhausted CD8+ T cells (P < 0.01), and increased the IFN-γ scores (P < 0.05). The results differed in MSI-H COADpatients (all P > 0.05). CONCLUSION: HRR gene mutations significantly increased immune activities in MSS COAD patients, implying the feasibility of the HRR-mut status as an immunotherapy response predictor in MSS COAD.
Authors: A B Schrock; C Ouyang; J Sandhu; E Sokol; D Jin; J S Ross; V A Miller; D Lim; I Amanam; J Chao; D Catenacci; M Cho; F Braiteh; S J Klempner; S M Ali; M Fakih Journal: Ann Oncol Date: 2019-07-01 Impact factor: 32.976
Authors: Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan Journal: J Clin Invest Date: 2017-06-26 Impact factor: 14.808
Authors: Russell Bonneville; Melanie A Krook; Esko A Kautto; Jharna Miya; Michele R Wing; Hui-Zi Chen; Julie W Reeser; Lianbo Yu; Sameek Roychowdhury Journal: JCO Precis Oncol Date: 2017-10-03
Authors: Patrick Danaher; Sarah Warren; Lucas Dennis; Leonard D'Amico; Andrew White; Mary L Disis; Melissa A Geller; Kunle Odunsi; Joseph Beechem; Steven P Fling Journal: J Immunother Cancer Date: 2017-02-21 Impact factor: 13.751
Authors: Dung T Le; Tae Won Kim; Eric Van Cutsem; Ravit Geva; Dirk Jäger; Hiroki Hara; Matthew Burge; Bert O'Neil; Petr Kavan; Takayuki Yoshino; Rosine Guimbaud; Hiroya Taniguchi; Elena Elez; Salah-Eddin Al-Batran; Patrick M Boland; Todd Crocenzi; Chloe E Atreya; Yi Cui; Tong Dai; Patricia Marinello; Luis A Diaz; Thierry André Journal: J Clin Oncol Date: 2019-11-14 Impact factor: 44.544
Authors: Theo A Knijnenburg; Linghua Wang; Michael T Zimmermann; Nyasha Chambwe; Galen F Gao; Andrew D Cherniack; Huihui Fan; Hui Shen; Gregory P Way; Casey S Greene; Yuexin Liu; Rehan Akbani; Bin Feng; Lawrence A Donehower; Chase Miller; Yang Shen; Mostafa Karimi; Haoran Chen; Pora Kim; Peilin Jia; Eve Shinbrot; Shaojun Zhang; Jianfang Liu; Hai Hu; Matthew H Bailey; Christina Yau; Denise Wolf; Zhongming Zhao; John N Weinstein; Lei Li; Li Ding; Gordon B Mills; Peter W Laird; David A Wheeler; Ilya Shmulevich; Raymond J Monnat; Yonghong Xiao; Chen Wang Journal: Cell Rep Date: 2018-04-03 Impact factor: 9.423